Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: An in vitro study

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages 148-152

  Romano, Eloisa ^a   Bellando Randone, Silvia ^a   Manetti, Mirko ^b   Bruni, Cosimo ^a   Lepri, Gemma ^a   Matucci Cerinic, Marco ^a   Guiducci, Serena ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Angiogenesis; Bosentan; Dermal microvascular endothelial cells; Systemic sclerosis

Indexed keywords

BOSENTAN; ANGIOGENIC FACTOR; ANGIOSTATIC PROTEIN; SULFONAMIDE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL INVASION; CELL VIABILITY; CHEMOINVASION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DERMAL MICROVASCULAR ENDOTHELIAL CELL; DRUG ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; SCLERODERMA; SERUM; SYSTEMIC SCLEROSIS; BLOOD; CASE CONTROL STUDY; CELL CULTURE; CELL MOTION; CELL SURVIVAL; DIFFUSE SCLERODERMA; DOSE RESPONSE; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM; PATHOPHYSIOLOGY; SKIN; VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; ANGIOSTATIC PROTEINS; CASE-CONTROL STUDIES; CELL MOVEMENT; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; SCLERODERMA, DIFFUSE; SKIN; SULFONAMIDES;

EID: 84946201676     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. van den HOOGEN F, KHANNA D, FRANSEN J et al.: 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013; 72: 1747-55.
2. MANETTI M, GUIDUCCI S, IBBA-MANNESCHI L, MATUCCI-CERINIC M: Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med 2010; 14: 1241-54.
3. MATUCCI-CERINIC M, KAHALEH B, WIGLEY FM: Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 2013; 65: 1953-62.
4. SHETTY N, DERK CT: Endothelin receptor antagonists as disease modifiers in systemic sclerosis. Inflamm Allergy Drug Targets 2011; 10: 19-26.
5. ABRAHAM D, DISTLER O: How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther 2007; 9 (Suppl. 2): S2.
6. SHI-WEN X, KENNEDY L, RENZONI EA et al.: Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis Rheum 2007; 56: 4189-94.
7. MAYES MD: Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 2003; 48: 1190-9.
8. SEO B, OEMAR BS, SIEBENMANN R, VONSEGESSER L, LUSCHER TF: Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994; 89: 1203-8.
9. VIGNON-ZELLWEGER N, HEIDEN S, MIYAU-CHI T, EMOTO N: Endothelin and endothelin receptors in the renal and cardiovascular systems. Life Sci 2012; 91: 490-500.
10. BAUER M, WILKENS H, LANGER F, SCHNEIDER SO, LAUSBERG H, SCHäFERS HJ: Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 2002; 105: 1034-6.
11. FROMMER KW, MüLLER-LADNER U: Expression and function of ETA and ETB receptors in SSc. Rheumatology (Oxford) 2008; 47 (Suppl. 5): v27-8.
12. LAGARES D, GARCIA-FERNANDEZ R, JIMENEZ CL et al.: Endothelin 1 contributes to the effect of transforming growth factor beta 1 on wound repair and skin fibrosis. Arthritis Rheum 2010; 62: 878-89.
13. COZZI F, PIGATTO E, RIZZO M et al.: Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study. Clin Rheumatol 2013; 32: 679-83.
14. MATUCCI-CERINIC M, DENTON CP, FURST DE et al.: Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011; 70: 32-8.
15. GUIDUCCI S, BELLANDO RANDONE S, BRUNI C et al.: Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clin Rheumatol 2012; 31: 1723-5.
16. CUTOLO M, ZAMPOGNA G, VREMIS L, SMITH V, PIZZORNI C, SULLI A: Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis. J Rheumatol 2013; 40: 40-5.
17. MANETTI M, GUIDUCCI S, ROMANO E et al.: Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res 2011; 109: e14-26.
18. MULLIGAN-KEHOE MJ, DRINANE MC, MOLLMARK J et al.: Antiangiogenic plasma activity in patients with systemic sclerosis. Arthritis Rheum 2007; 56: 3448-58.
19. FLEMING JN, NASH RA, MCLEOD DO et al.: Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS One 2008; 3: e1452.
20. NGCOZANA T, ONG V, DENTON CP: Management of digital vasculopathy in systemic sclerosis: benefits of multiple courses of endothelin-1 receptor antagonists. BMJ Case Rep 2014 Mar 28; 2014.